Credit Suisse’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $9.4M | Sell |
201,268
-16,708
| -8% | -$788K | 0.01% | 938 |
|
|
2023
Q4 | $10.4M | Sell |
217,976
-30,741
| -12% | -$1.19M | 0.01% | 906 |
|
|
2023
Q3 | $8.87M | Buy |
248,717
+40,030
| +19% | +$1.59M | 0.01% | 953 |
|
|
2023
Q2 | $9.63M | Buy |
208,687
+31,467
| +18% | +$1.46M | 0.01% | 944 |
|
|
2023
Q1 | $7.11M | Buy |
177,220
+17,900
| +11% | +$768K | 0.01% | 1096 |
|
|
2022
Q4 | $7.38M | Buy |
159,320
+18,065
| +13% | +$711K | 0.01% | 1073 |
|
|
2022
Q3 | $5.85M | Sell |
141,255
-300
| -0.2% | -$15.4K | 0.01% | 1171 |
|
|
2022
Q2 | $8.45M | Buy |
141,555
+19,128
| +16% | +$1.18M | 0.01% | 1005 |
|
|
2022
Q1 | $8.89M | Buy |
122,427
+21,983
| +22% | +$1.53M | 0.01% | 1101 |
|
|
2021
Q4 | $8.45M | Buy |
100,444
+28,008
| +39% | +$2.28M | ﹤0.01% | 1632 |
|
|
2021
Q3 | $6.53M | Sell |
72,436
-20,332
| -22% | -$1.84M | ﹤0.01% | 1841 |
|
|
2021
Q2 | $8.85M | Buy |
92,768
+25,180
| +37% | +$2.62M | ﹤0.01% | 1646 |
|
|
2021
Q1 | $7.7M | Sell |
67,588
-26,318
| -28% | -$3.58M | ﹤0.01% | 1758 |
|
|
2020
Q4 | $13M | Buy |
93,906
+21,771
| +30% | +$2.58M | 0.01% | 1419 |
|
|
2020
Q3 | $5.93M | Sell |
72,135
-21,775
| -23% | -$1.8M | ﹤0.01% | 1679 |
|
|
2020
Q2 | $7.34M | Sell |
93,910
-66,328
| -41% | -$4.39M | 0.01% | 1466 |
|
|
2020
Q1 | $7.12M | Buy |
160,238
+26,869
| +20% | +$1.4M | 0.01% | 1346 |
|
|
2019
Q4 | $5.7M | Buy |
133,369
+43,865
| +49% | +$1.81M | ﹤0.01% | 1792 |
|
|
2019
Q3 | $3.83M | Buy |
89,504
+44,777
| +100% | +$2.43M | ﹤0.01% | 1968 |
|
|
2019
Q2 | $2.84M | Buy |
44,727
+3,437
| +8% | +$219K | ﹤0.01% | 2183 |
|
|
2019
Q1 | $2.86M | Buy |
41,290
+2,075
| +5% | +$119K | ﹤0.01% | 2108 |
|
|
2018
Q4 | $1.71M | Sell |
39,215
-158
| -0.4% | -$8.63K | ﹤0.01% | 2357 |
|
|
2018
Q3 | $3M | Sell |
39,373
-14,033
| -26% | -$1.14M | ﹤0.01% | 2053 |
|
|
2018
Q2 | $4.1M | Sell |
53,406
-4,441
| -8% | -$287K | ﹤0.01% | 1875 |
|
|
2018
Q1 | $2.95M | Buy |
57,847
+7,457
| +15% | +$376K | ﹤0.01% | 2109 |
|
|
2017
Q4 | $2.34M | Sell |
50,390
-77,633
| -61% | -$3.81M | ﹤0.01% | 2315 |
|
|
2017
Q3 | $6.82M | Buy |
128,023
+1,610
| +1% | +$95.4K | 0.01% | 1515 |
|
|
2017
Q2 | $7.85M | Sell |
126,413
-18,029
| -12% | -$1.09M | 0.01% | 1347 |
|
|
2017
Q1 | $9.79M | Buy |
144,442
+26,502
| +22% | +$2.02M | 0.01% | 1240 |
|
|
2016
Q4 | $8.29M | Sell |
117,940
-1,436
| -1% | -$102K | 0.01% | 1316 |
|
|
2016
Q3 | $8.47M | Sell |
119,376
-21,811
| -15% | -$1.39M | 0.01% | 1309 |
|
|
2016
Q2 | $6.91M | Buy |
141,187
+56,038
| +66% | +$3.62M | 0.01% | 1414 |
|
|
2016
Q1 | $5.39M | Buy |
85,149
+28,705
| +51% | +$1.88M | 0.01% | 1471 |
|
|
2015
Q4 | $6.33M | Buy |
56,444
+2,147
| +4% | +$215K | 0.01% | 1419 |
|
|
2015
Q3 | $5.23M | Buy |
54,297
+2,120
| +4% | +$243K | 0.01% | 1530 |
|
|
2015
Q2 | $5.34M | Buy |
52,177
+18,500
| +55% | +$1.44M | 0.01% | 1678 |
|
|
2015
Q1 | $2.09M | Buy |
33,677
+13,412
| +66% | +$745K | ﹤0.01% | 2363 |
|
|
2014
Q4 | $889K | Buy |
20,265
+8,913
| +79% | +$408K | ﹤0.01% | 3239 |
|
|
2014
Q3 | $642K | Buy |
+11,352
| New | +$571K | ﹤0.01% | 3439 |
|
Other funds holding RARE
RI
Credit Suisse's RARE Position: Q1 2024 in Review
Credit Suisse reduced its Ultragenyx Pharmaceutical (RARE) stake by 7.7% in Q1 2024, selling an estimated $788K and leaving 201,268 shares worth $9.4M. The position accounts for 0.01% of the portfolio, ranked #938.
Credit Suisse first reported a position in RARE in Q3 2014 and has held it in 39 quarters since. The position peaked at $13M in Q4 2020. 269 funds tracked by Wall St. Rank hold RARE as of Q1 2024.
- Credit Suisse held 201,268 shares of Ultragenyx Pharmaceutical worth $9.4M as of Q1 2024.
- Credit Suisse sold 16,708 Ultragenyx Pharmaceutical shares in Q1 2024, an estimated $788K.
- Ultragenyx Pharmaceutical made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #938 holding.
- Credit Suisse first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 39 quarters since.
- Credit Suisse's Ultragenyx Pharmaceutical position peaked at $13M in Q4 2020.
- 269 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.